Moleculin Biotech, Inc. 8-K

What Happened
On March 19, 2026, Moleculin Biotech, Inc. (MBRX) announced its financial results for the year ended December 31, 2025 and provided recent operational highlights via a press release. The company filed this information on Form 8‑K under Item 2.02 (Results of Operations and Financial Condition) and attached the press release as Exhibit 99.1.

Key Details

• Filing date: March 19, 2026 (Form 8‑K, Item 2.02).
• Period reported: year ended December 31, 2025.
• The press release with the financial results and operational highlights is attached as Exhibit 99.1 to the 8‑K.
• The 8‑K does not disclose additional financial tables in-line; investors should review Exhibit 99.1 for full figures and details.

Why It Matters
This filing is the company’s official disclosure of its full‑year 2025 performance and recent operational developments — essential information for evaluating Moleculin’s financial health, cash position, and progress on clinical or business milestones. Retail investors should read the attached press release (Exhibit 99.1) for specific numbers (revenue, net income/loss, cash runway) and any management commentary, and compare those figures to prior quarters and company guidance when making investment decisions. This 8‑K does not report any management changes, mergers, or acquisitions.